Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial

Background: Glaceum Inc. has proposed HSG4112, a structural analogue of glabridin, as a novel anti-obesity compound. Animal studies and phase I human trials have shown that HSG4112 improves energy consumption, normalises weight, and is safe and drug-resistant. Based on these results, the company pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Kyungha, Oh, Bumjo, Koo, Hye Yeon, Kim, Yang-Hyun, Lee, Ji-Won, Lee, Sangsub, Kim, Youngah, Kwon, Hyuktae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483829/
https://www.ncbi.nlm.nih.gov/pubmed/37693914
http://dx.doi.org/10.3389/fphar.2023.1177539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483829/
https://www.ncbi.nlm.nih.gov/pubmed/37693914
http://dx.doi.org/10.3389/fphar.2023.1177539

Ejemplares similares